Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06111014 · ClinicalTrials.gov registry record · Phase 3
Continuation Study for Latozinemab
A Phase 3 study, sponsored by Alector.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT06111014 is a Phase 3 study that was terminated before completion, run by Alector. The registered enrollment target is 17 participants.
The verdict
NCT06111014, a Phase 3 study, was terminated before completion, sponsored by Alector.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Interventions
- DRUG Latozinemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06111014
The ClinicalTrials.gov registry entry for NCT06111014 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Latozinemab is the first listed.
NCT06111014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06111014 about?
NCT06111014 is a clinical study titled "Continuation Study for Latozinemab". Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
What is the current status of trial NCT06111014?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2023-12-08. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT06111014?
The interventions under investigation include: Latozinemab (DRUG).
Who is sponsoring clinical trial NCT06111014?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.